Clinical Trials Logo
  1. Home
  2. Pulmonary Fibrosis
  3. NCT06275295
  4. Details
NCT06275295 Clinical Trial

A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis

Pulmonary Fibrosis Clinical Trial

Official title:
Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis：a Multicenter Retrospective Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT06275295
Other study ID # ZRJY2021-BJ08-03-01-01
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 20, 2024
Est. completion date December 31, 2024

Study information
Verified date February 2024
Source China-Japan Friendship Hospital
Contact Gang Hou, Professor
Phone 1384005481
Email hougangcmu@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC） in progressive pulmonary fibrosis.

Description:

The goal of this observational study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC） in progressive pulmonary fibrosis. The main question it aims to answer are: • The diagnostic rate of MDD1 or MDD2 based on TBLC. • The rate of hemorrhage, pneumothorax, acute ILD exacerbation and mortality. Participants' medical records will be collected by us.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 300
Est. completion date December 31, 2024
Est. primary completion date December 24, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Patients with PPF, =18 years of age, unclassified ILD, HRCT =3 months, forced vital capacity (FVC)=50% predicted value, pulmonary carbon monoxide diffusion (DLCO)=35% predicted value, echocardiography =12 months, estimated pulmonary systolic blood pressure =40 mmHg, Body mass index (BMI)=35 kg/m2. Exclusion Criteria: Patients with platelet counts below 50,000e+9/L or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
China-Japan Friendship Hospital

Outcome
Type Measure Description Time frame Safety issue
Primary The diagnostic rate of MDD2 based on TBLC the diagnostic rate of progressive pulmonary fibrosis after Transbronchial Cryobiopsy December,31,2024
Secondary The diagnostic rate of MDD1 the diagnostic rate of progressive pulmonary fibrosis before Transbronchial Cryobiopsy December,31,2024
See also
  Status Clinical Trial Phase
Recruiting NCT04638517 - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis Phase 2
Recruiting NCT05299333 - Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis N/A
Terminated NCT04119115 - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT01417156 - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) Phase 2
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3
Completed NCT00001596 - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome Phase 2
Completed NCT00052052 - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT01442779 - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Recruiting NCT04864990 - Dyspnea and Idiopathic Pulmonary Fibrosis
Completed NCT01961362 - Supplemental Oxygen in Pulmonary Fibrosis
Completed NCT01271842 - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study N/A
Completed NCT00650091 - Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Phase 3
Active, not recruiting NCT00258544 - Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Enrolling by invitation NCT04930289 - Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Completed NCT02055222 - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Enrolling by invitation NCT06327360 - Illness Expectations in Pulmonary Fibrosis